-
Man City whistleblower Pinto to stay under police protection
-
BMW pulls car lease offer from German far-right politician
-
US leads fresh Ukraine peace push with Miami talks
-
Brazil election offers Jair Bolsonaro a shot at revenge
-
Verstappen continues resurgence with pole for Singapore sprint
-
Man Utd boss Carrick 'personally' affected by Man City verdict
-
Cuban ration book, symbol of the revolution, gathers dust
-
Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to $10–$11 Million and Reaffirms $400–$460 Million Fiscal 2027 Outlook
-
Stocks advance, oil retreats as Trump rules out pre-vote Iran attack
-
Red Bull's Verstappen takes pole position for Singapore GP sprint race
-
Man City case causing 'uncertainty' for whole Premier League, says Iraola
-
Chelsea star Palmer 'committed' to England insists Alonso
-
Talks with Iran can only succeed without threats, president says
-
OpenAI denies firing researchers over AI safety warnings
-
Home hope Zheng sets up Mertens clash in China Open semis
-
Turkey warns opposition, press over investment fund crisis
-
Lombardia promises gripping end to season in Pogacar absence
-
Hurricane Isaias now major storm as it heads to US Gulf Coast
-
Barca skipper Raphinha out against Getafe and Galatasaray
-
Djokovic crashes out of Shanghai Masters in his first match
-
MEXC and Payward Highlight Collaboration as Crypto and TradFi Converge at TOKEN2049
-
EU says Turkey's crackdown on rights hampers membership bid
-
EU states agree beefed-up European financial markets watchdog
-
Two Renoir paintings stolen in France recovered: mayor
-
Eritrea, Ethiopia trade barbs as Tigray rebels retreat
-
German leader outraged at Schroeder birthday visit to Putin
-
Kompany 'proud' of Man City success despite guilty verdict
-
Stocks up, oil retreats as Trump rules out pre-vote Iran attack
-
Man City will win appeal over financial charges, says Maresca
-
South African judge Navi Pillay wins Nobel Peace Prize
-
Fernandez logs record lap at Indonesia MotoGP practice
-
'I completely trust the club,' says Man City boss Maresca
-
Navi Pillay: S.Africa's global rights activist and Nobel winner
-
'10 out of 10' Quintana reminisces over dream Vuelta win
-
Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading
-
Maddinson given shock recall but fails to score
-
Russell goes fastest in practice for smoggy Singapore GP
-
Navi Pillay, South African rights champion, wins Nobel Peace Prize
-
For exiled Russian director Zvyagintsev, triumph without belonging
-
Saudi Arabia says three killed at airport as Yemen war expands
-
Home hope Zheng storms into China Open semi-finals
-
Everton's US owners mull sale of club two years after takeover
-
Zverev churns out win in Shanghai Masters opener
-
Ukraine takes Russia fight to 'scorching sands' of Sahel
-
Hurricane Isaias strengthens en route to US Gulf Coast
-
Chinese AI tool pulled to prevent 'misuse' after South Korea hacks
-
US activists deploy poll volunteers over Trump intimidation fears
-
Asian stocks mostly up as traders weigh AI, oil dips after surge
-
Saint Laurent designer Vaccarello leaves after glittering decade
-
Walking through flames: orangutans rescued in Indonesia fires
Bakar Labs Helps Companies Raise More Than $1 Billion in Its First Four Years of Operation
Life science incubator part of UC Berkeley's wider ecosystem, which has consistently ranked the number one university for entrepreneurs1
BERKELEY, CA / ACCESS Newswire / February 24, 2026 / Bakar Labs, UC Berkeley's flagship incubator supporting innovation in life sciences, energy and materials, today announced that its companies have raised more than $1 billion in cumulative funding over its first four years of operation. This underscores both the quality of its science and the resilience of its entrepreneurial ecosystem during a period of time when early-stage biotech funding sharply declined. Since its official opening in February 2022, Bakar Labs has supported more than 50 companies developing therapeutics and diagnostics. Collectively, those companies have created more than 500 jobs across California, underscoring the incubator's role in translating academic research into commercial ventures with tangible economic impact.
"This milestone reflects the purpose Bakar Labs was built to serve," said David Schaffer, director of Bakar Labs and UC Berkeley professor of chemical and biomolecular engineering. "Our mission is to help scientific discovery move out of the lab and toward real-world impact. Seeing that vision come to fruition through company formation, job creation and sustained investment signals the strength of this model and the opportunity ahead."
The $1 billion threshold was officially crossed following a $100 million Series A funding round by Addition Therapeutics, a UC Berkeley spinout and former Bakar Labs tenant. Co-founded by UC Berkeley professor Kathleen Collins, the company is creating one-time-dose therapies for chronic and rare diseases, an area where long development timelines make early and sustained funding essential. CEO Ron Park, MD said of the funding, "The fundamental truth about biotechs is you typically don't have revenue until the drug is approved, which in many cases takes 10 years or longer. So this funding is necessary to go through the very expensive drug discovery and development process."
Since its inception, Bakar Labs has provided lab infrastructure, mentorship and strategic connections within UC Berkeley's innovation ecosystem, including Berkeley SkyDeck, the Life Sciences Entrepreneurship Center, CITRIS Foundry and eight campus-affiliated venture funds. In addition, affiliations with more than 25 large companies provide tenants with access to industry resources. The incubator plans significant expansion in the coming years, including two new biotech sites and Bakar Labs for Energy and Materials, which will open in 2028.
"Beyond benches and scientists, relationships and trust are essential to the business of drug development. Investors and pharma partners must know we will be responsible stewards of funding and engage in rigorous science. The ecosystem at Bakar Labs was the first to connect us with world-leading researchers, business advisors, investors and pharma," said Sophia Lugo, co-founder and CEO of Radar Therapeutics. "QB3, BEVC, Amgen, Lilly, AbbVie, J&J, members of our SAB and more came to us at Bakar Labs. We started with a single bench and desk funded by AbbVie and left with the talent, funding and connections to industry necessary in building our groundbreaking RNA therapeutics engine."
While many tenant companies originate from UC Berkeley research, Bakar Labs also attracts founders from outside the university. Current tenant companies include startups co-founded by researchers from industry and other leading academic institutions, reinforcing the incubator's broader pull across the California life science community and beyond.
"Bakar Labs has been instrumental in helping advance high-quality biotech research emerging from UC Berkeley into viable companies," said Corey Goodman, managing partner at venBio Partners and a member of the Bakar Labs board. "That progress is particularly notable given the difficult fundraising environment early-stage biotech companies have faced in recent years, making the more than $1 billion raised across current and alumni companies a strong signal of the science and the ecosystem supporting it."
***
About Bakar Labs
Bakar Labs is UC Berkeley's flagship incubator supporting innovation in life sciences, energy and materials. Operated by QB3, Bakar Labs provides extensive equipment, lab and office facilities, and a community of like-minded entrepreneurs to help startups grow. Bakar Labs can support as many as 50 early-stage companies from around the world focused on translating innovations that promise to improve human and planetary health. No UC affiliation is required to join. For information about how to join or form a partnership, visit bakarlabs.org.
Media inquiries
Songue PR for Bakar Labs
[email protected]
SOURCE: Bakar Bio Labs
View the original press release on ACCESS Newswire
N.Mitchell--AT